



1/21




Fig. 1




Fig. 2

2/21




Fig. 3

3/21




Fig. 4

4/21




Fig. 5

5/21




Fig. 6

6/21




Fig. 7

7/21




Fig. 8

8/21




Fig. 9

9/21




Fig. 10




Fig. 11

10/21




Fig. 12




Fig. 13

11/21




Fig. 14

12/21

INFLAMMATION




Fig. 15A

**EPILIGAMENOUS
REGENERATION**




Fig. 15B

PROLIFERATION




Fig. 15C

REMODELING




Fig. 15D

13/21




Fig. 16




Fig. 17

14/21




Fig. 18




Fig. 19

15/21




Fig. 20A




Fig. 20B

16/21

INTACT HUMAN ACL




Fig. 21A

**GEL WITH CELLS AT
3 HOURS OF CULTURE**




Fig. 21B

**GEL WITH CELLS AT
3 DAYS OF CULTURE**




Fig. 21C

**GEL WITH CELLS AT
9 DAYS OF CULTURE**




Fig. 21D

17/21




Fig. 22




Fig. 23

18/21




Fig. 24




Fig. 25

19/21




Fig. 26

20/21




Fig. 27




Fig. 28

21/21




Fig. 29